The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of…
If the biotech titan that’s the focus of today’s article is going to improve its growth prospects, it may have to go acquisition shopping in the next few months – and one of the three companies that the author highlights could be its target, as he notes that all three are acquisitions that “the biotech could easily afford and that…
When it comes to finding the best biotech stocks to buy, the author of today’s article acknowledges that it “can be tricky given that volatility often haunts the space.” Nonetheless, he proceeds to highlight three biotech stocks to watch – two of which are working on COVID-19 vaccines while the third may be worth a look even though the company…
In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners,…
The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise…
In regards to the two relatively young biotech stocks with monster potential discussed in today’s article, the author has the following to say: “…they have deeply compelling projects that aim to cure or fully mitigate a handful of different medical conditions that were once considered intractable. Both have demonstrated excellent progress so far, not to mention financial strength. It’ll take…
UBS just initiated coverage on nine biotech stocks, four of which its analysts have given ‘Buy’ ratings – and two of those, the analysts believe, could soar by more than 50%. For these four biotech stocks that investors should buy, according to UBS, as well as the five biotech stocks that the firm initiated coverage on at a ‘Neutral’ rating,…
Important industry conferences and events (such as the recent ENA 2020 symposium where cancer researchers shared new data on drug candidates from various biotech companies), upcoming data releases and big upticks in insider buying make the five biotech penny stocks highlighted in today’s article ones to watch this week and in the weeks ahead. For these five biotech penny stocks…
Investors looking for profitable pandemic plays have a plethora of biotech firms to choose from. The one that’s the subject of today’s article, however, may not be one of them, despite the fact that some are betting on it as a COVID play. In fact, one market analyst has warned “Investors beware” in regards to this stock. For the stock…
“Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one’s entire investment thanks to their vulnerability to catalytic events,” acknowledges the author of today’s article before proceeding to identify nine biotech stocks with key catalysts in the final months of 2020. For these nine stocks and their respective fourth-quarter catalysts and price targets, CLICK HERE.